Paulson KG, Gupta D, Kim TS, et al. Age-specific incidence of melanoma in the United States. JAMA Dermatol. 2020;156:57–64.

Article  PubMed  Google Scholar 

Curti BD, Faries MB. Recent advances in the treatment of melanoma. N Engl J Med. 2021;384:2229–40.

Article  CAS  PubMed  Google Scholar 

Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535–46. This landmark study demonstrated the durable survival benefit of combination immune checkpoint inhibitor therapy in metastatic melanoma.

Article  CAS  PubMed  Google Scholar 

D’Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol. 2017;35:226–35.

Article  CAS  PubMed  Google Scholar 

Mao L, Qi Z, Zhang L, Guo J, Si L. Immunotherapy in acral and mucosal melanoma: current status and future directions. Front Immunol. 2021;12: 680407.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Piulats JM, Espinosa E, de la Cruz ML, et al. Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: an open-label, multicenter, phase II trial by the spanish multidisciplinary melanoma group (GEM-1402). J Clin Oncol. 2021;39:586–98.

Article  CAS  PubMed  Google Scholar 

Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:1315–27.

Article  CAS  PubMed  Google Scholar 

Dummer R, Flaherty K, Robert C, et al. Five-year overall survival (OS) in COLUMBUS: a randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. J Clin Oncol. 2021;39:9507–9507.

Article  Google Scholar 

Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2019;30:1848.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877–88.

Article  PubMed  Google Scholar 

Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381:626–36.

Article  CAS  PubMed  Google Scholar 

Ascierto PA, McArthur GA, Dréno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17:1248–60.

Article  CAS  PubMed  Google Scholar 

Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371:1867–76.

Article  PubMed  Google Scholar 

Van Allen EM, Miao D, Schilling B, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350:207–11.

Article  PubMed  PubMed Central  Google Scholar 

Berger MF, Hodis E, Heffernan TP, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485:502–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell. 2012;150:251–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krauthammer M, Kong Y, Ha BH, et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 2012;44:1006–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371:2189–99.

Article  PubMed  PubMed Central  Google Scholar 

Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garibyan L, Fisher DE. How sunlight causes melanoma. Curr Oncol Rep. 2010;12:319–26.

Article  CAS  PubMed  Google Scholar 

Raaijmakers MI, Widmer DS, Narechania A, et al. Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance. Oncotarget. 2016;7:77163–74.

Article  PubMed  PubMed Central  Google Scholar 

Garcia-Alvarez A, Ortiz C, Munoz-Couselo E. Current perspectives and novel strategies of NRAS-mutant melanoma. Onco Targets Ther. 2021;14:3709–19.

Article  PubMed  PubMed Central  Google Scholar 

Carlino MS, Haydu LE, Kakavand H, et al. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. Br J Cancer. 2014;111:292–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 2013;14:249–56.

Article  CAS  PubMed  Google Scholar 

Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:435–45.

Article  CAS  PubMed  Google Scholar 

Gogas H, Dreno B, Larkin J, et al. Cobimetinib plus atezolizumab in BRAF(V600) wild-type melanoma: primary results from the randomized phase III IMspire170 study. Ann Oncol. 2021;32:384–94.

Article  CAS  PubMed  Google Scholar 

Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13:782–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Coupe N, Corrie P, Hategan M, et al. PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. Eur J Cancer. 2015;51:359–66.

Article  CAS  PubMed  Google Scholar 

Lebbe C, Dutriaux C, Lesimple T, et al. Pimasertib versus dacarbazine in patients with unresectable NRAS-mutated cutaneous melanoma: phase II, randomized, controlled trial with crossover. Cancers (Basel). 2020; 12.

Sosman JA, Kittaneh M, Lolkema MPJK, et al. A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity. J Clin Oncol. 2014;32:9009–9009.

Article  Google Scholar 

Schuler M, Zimmer L, Kim KB, et al. Phase Ib/II trial of ribociclib in combination with binimetinib in patients with NRAS-mutant melanoma. Clin Cancer Res. 2022.

Algazi AP, Esteve-Puig R, Nosrati A, et al. Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma. Pigment Cell Melanoma Res. 2018;31:110–4.

Article  CAS  PubMed  Google Scholar 

Wang X, Si L, Mao L, et al. A first-in-human phase I/II study of HL-085, a MEK inhibitor, in chinese patients with NRASm advanced melanoma. J Clin Oncol. 2020;38:10047–10047.

Article  Google Scholar 

Kinsey CG, Camolotto SA, Boespflug AM, et al. Protective autophagy elicited by RAF–>MEK–>ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med. 2019;25:620–7. This preclinical study provides that rationale for combining MEK and autophagy inhibition in NRAS-mutated melanoma.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma XH, Piao SF, Dey S, et al. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest. 2014;124:1406–17.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martin S, Dudek-Peric AM, Maes H, et al. Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells. Biochem Pharmacol. 2015;93:290–304.

Article  CAS  PubMed  Google Scholar 

Mulcahy Levy JM, Zahedi S, Griesinger AM, et al. Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. Elife. 2017; 6.

Sueda T, Sakai D, Kawamoto K, et al. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells. Sci Rep. 2016;6:18949.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xie X, Koh JY, Price S, White E, Mehnert JM. Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma. Cancer Discov. 2015;5:410–23.

Article  CAS